Syndax Pharmaceuticals, Inc. (SNDX) Cash Flow Statement

The gap between net income and operating cash flow is narrow, which suggests that reported losses are largely cash-real rather than driven by accruals or non-cash charges. Stock-based compensation of $15.3M in 2026Q3 explains only part of the $49.4M net loss, so the remaining burn appears to reflect genuine research and operating outlays. This pattern suggests earnings quality is not the concern here; the question is how long the cash runway can sustain this burn rate.

Free cash flow has been negative throughout the period, and the margin trend appears volatile rather than converging toward breakeven. Because revenue is driven by lumpy collaboration milestones, the margin swings reflect timing of receipts as much as underlying operations. Investors should monitor whether non-recurring milestone income is masking a sustained operating deficit that persists between payment events.

These swings are consistent with milestone receipts being recognized or collected unevenly rather than with a structural change in collection efficiency. The sign reversals imply that quarter-to-quarter operating cash flow is a poor guide to run-rate burn. Analysts should evaluate trailing multi-quarter totals to separate working capital noise from the underlying cash consumption.

The absence of shareholder distributions is expected for a pre-commercial biotech, but it also means the company has no internal surplus to redeploy. With operating cash outflows persisting, the balance sheet appears to depend on existing reserves and potential future capital raises. Investors should treat the runway as the key constraint rather than capital allocation quality at this stage.